Everyone says that we are just waiting for the next best thing in MS treatment. Maybe this is it.
There’s a new vaccine on the horizon that could stop a terrible disease in its tracks.Multiple sclerosis is an autoimmune disease that affects nearly half a million Americans.There’s word a vaccine is showing promise in early clinical trials.The vaccine is BHT-3009. It contains DNA of healthy human myelin protein.Myelin is the insulation that protects nerve fibers. It is destroyed in MS patients.The vaccine delivers new DNA to the body to stop the immune system from attacking the nervous system.So far, patients have not suffered any side affects.Researchers hope to see if it can stop the disease from progressing or even reverse some of the symptoms of MS.The manufacturer, Bayhill Therapeutics, funded the study.
The only disturbing thing (to me) is that in the clinical trials exlusion criteria it lists…..
Prior therapy with natalizumab (Tysabri).
Let’s hope that this is not an exclusion criteria of the actual vaccine should it turn out to be released!
This came from the NMSS Website. Listed below are a few other websites you may be interested in if researching BHT-3009.
Results Published on BHT-3009, Experimental DNA Vaccine Treatment for MS
August 15, 2007
View or print this bulletin in its original format (PDF)*
An early-phase study of BHT-3009 (Bayhill Therapeutics), both alone and in combination with Lipitor® (atorvastatin, Pfizer, Inc.) found the drug to be safe and to induce a beneficial immune response in relapsing-remitting+ or secondary-progressive MS**. BHT-3009 is a vaccine containing genetic material that instructs cells to produce myelin basic protein (MBP), a component of myelin, an immune target in MS. Lipitor is a cholesterol-lowering drug under study for its effects on immune function in MS. Amit Bar-Or, MD (Montreal Neurological Institute) and colleagues published their findings in the Archives of Neurology (2007;64: early online publication, August 13). Results of the study, funded by Bayhill Therapeutics, were originally reported at the Annual Meeting of the American Academy of Neurology in 2006.
Details: Investigators randomly assigned 30 people with relapsing-remitting or secondary-progressive MS to either receive BHT-3009 (intramuscular injections in weeks 1, 3, 5, 9) with or without Lipitor (80 mg per day, oral capsules) or inactive placebo alone for 13 weeks. Those on placebo alone were later switched to BHT-3009 with or without Lipitor. Immune changes observed in the treatment groups included a decrease in attacking T cells, and in immune proteins targeting MBP. There was a reduction in tissue damage observed on imaging scans in the treatment groups compared with placebo, but the difference was not statistically significant. Adverse events were mild to moderate, and were similar in the groups taking BHT-3009 and placebo.
The authors note that, based on these results, a one-year, placebo-controlled clinical trial of BHT-3009 alone is underway in 290 people with relapsing-remitting MS; this study has completed enrollment. Further information can be found on the clinicaltrials.gov website, at www.clinicaltrials.gov/ct/show/NCT00382629.